2022
中期報告
2
4
8
37
67
68
69
71
72
74
122
127
1 2022
Margaret Han Dugan 3
Ranjeev Krishana
Donald W. Glazer
Anthony C. Hooper Michael Goller
Anthony C. Hooper
Alessandro Riva 1
Margaret Han Dugan 1
Donald W. Glazer
Michael Goller
Corazon (Corsee) D. Sanders
Ranjeev Krishana
Margaret Han Dugan 1
Thomas Malley
Michael Goller
Alessandro Riva 1
Thomas Malley
Corazon (Corsee) D. Sanders
Alessandro Riva 1
Thomas Malley
Anthony C. Hooper
Anthony C. Hooper
Margaret Han Dugan 2
Corazon (Corsee) D. Sanders
Ranjeev Krishana
Corazon (Corsee) D. Sanders
* 2022 1 31
2022 6 22
1. 2022 2 1
2. 2022 2 25
3. 2022 9 13
2022 2
(FCG, HKFCG)
Vistra Corporate Services (HK) Limited
Mourant Ozannes
183
Ernst & Young LLP
17 1712-1716
Mourant Governance Services (Cayman) Limited
94 Solaris Avenue, Camana Bay
Mourant Governance Services Grand Cayman KY1-1108
(Cayman) Limited Cayman Islands
94 Solaris Avenue
Camana Bay
Grand Cayman KY1-1108
Cayman Islands 06160
www.beigene.com
3 2022
2022 4
5 2022
/
10-K
2021 12 16
2024
2021 12 31
2022 6
7 2022
3
(BTK)
PD-1
PARP1 PARP2
13
Novartis Pharma AG
2,500
40 80
30
3 16,000
CMO
2010 29
8,600
2022 8
2022 9 20 (NICE)
(BR)
(WM)
2022 9 19 (EMA) (CHMP)
CD20 (MZL)
2022 9 10 2022 (European Society for Medical Oncology,
ESMO) PD-1
2022 8 23 NMPA
(ESCC) (sBLA)
2022 8 9 3 RATIONALE 301
(HCC) (OS)
600
2022 7 14 FDA
ESCC
(2L) (BLA) FDA
BLA FDA
2022 6 30 2022 (ESMO) RATIONALE 306
RATIONALE 306 3
ESCC
2022 6 21 NMPA
PD-L1
(G/GEJ) sBLA
2022 6 13
(MCL) NewBridge Pharmaceuticals
(MENA)
MENA
9 2022
2022 6 13
(CLL) (SLL)
(sNDA) FDA (PDUFA) 2023
1 20 FDA PDUFA
sNDA 3 ALPINE
(IRC) CLL SLL
(ORR) 2022 4 11
2022 6 10 NMPA
(NPC)
1. 800
ociperlimab TIGIT
BGB-11417 Bcl-2
2022 BGB-A445
OX40 surzebiclimab TIM3 BGB-10188 PI3Kδ BGB-15025 HPK-1
BGB-16673 BTK CDAC BGB-23330 TYK2 BGB-24714 SMAC
50
2022 10
2.
2,500
CRO
3.
3,100
4.
WM
50
5.
11 2022
2021 1
(1)
(2)
2022 12
2021 12
TIGIT
5
(1) (2)
(3)
13 2022
BTK
PD-1
TIGIT
PARP1 PARP2
BGB-15025 1(HPK1)
2022 14
BGB-11417 Bcl-2
BGB-A445 OX40
BGB-16673 BTK CDAC
BGB-A425 TIM-3
BGB-10188 PI3Kδ
BGB-23339 2(TYK2)
LBL-007 LAG-3
Sitravatinib Mirati Therapeutics, Inc Mirati
ZW25(Zanidatamab) ZW49 Zymeworks Inc Zymeworks HER2
(BAT1706)
15 2022
2022 16
ADS
2021 12
17 2022
2022 2021 6 30
6 30
2022 2021 %
566,084 244,741 321,343 131.3%
82,114 511,123 (429,009) (83.9)%
648,198 755,864 (107,666) (14.2)%
136,410 68,948 67,462 97.8%
768,122 676,817 91,305 13.5%
625,976 414,395 211,581 51.1%
376 375 1 0.3%
1,530,884 1,160,535 370,349 31.9%
(882,686) (404,671) (478,015) 118.1%
21,502 (9,045) 30,547 (337.7)%
(117,650) (4,990) (112,660) 2,257.7%
(978,834) (418,706) (560,128) 133.8%
26,889 (4,860) 31,749 (653.3)%
(1,005,723) (413,846) (591,877) 143.0%
2022 18
2021 2022 6 30
2022 6 30 2021 6 30 7.559
6.482 14.2% 6.50
2022 2021 6 30
6 30
2022 2021 %
566,084 244,741 321,343 131.3%
– 484,646 (484,646) (100.0)%
24,240 26,477 (2,237) (8.4)%
52,497 – 52,497
5,377 – 5,377
82,114 511,123 (429,009) (83.9)%
648,198 755,864 (107,666) (14.2)%
6 30
2022 2021 %
233,072 64,513 168,559 261.3%
192,522 123,758 68,764 55.6%
41,576 26,775 14,801 55.3%
29,008 17,792 11,216 63.0%
21,396 – 21,396
19,798 – 19,798
8,946 6,961 1,985 28.5%
8,405 – 8,405
4,577 2,221 2,356 106.1%
6,784 2,721 4,063 149.3%
566,084 244,741 321,343 131.3%
19 2022
2022 6 30 131.3% 5.661 2.447
2021 8 2022 1
2022 1
2022 2022 6 30
2022 6 30
2.331 261.3% 2022 6
30
1.563 2,600 500.5%
2022 6 30
7,020 82.7% (CLL) (SLL)
2022 6 30
1.925 1.238
55.6% 2022 6 30
2021 3 1
2021 2,810
2021
2022 6 30 8,210
2022 6 30 2,420
5,250
540 2021 6 30 5.111
4.846 2021 6 30
2,650 3
2021 6 30 6,890 2022 6 30 1.364
2021 8
2022 1
2022 20
2022 6 30 4.297 2021 6 30 1.758
71.8%
2022 6 30 75.9%
2022 1
2022 6 30 2021 6 30
2021 6 30 6.768 9,130 13.5% 2022 6
30 7.681 2022 2021 6 30
6 30
2022 2021 %
232,009 219,433 12,576 5.7%
– 53,500 (53,500) (100.0)%
1
46,789 55,330 (8,541) (15.4)%
278,798 328,263 (49,465) (15.1)%
489,324 348,554 140,770 40.4%
768,122 676,817 91,305 13.5%
1
2022 6 30 9,240 4,680
4,560
21 2022
2022 6 30 5,350
1.408 40.4% 4.893
6,500
4,320
2,570
1,590
910
2021 6 30 4.144 2.116 51.1% 2022
6 30 6.260
1.174
3,710
2022 22
3,670
2,030
2021 6 30 900 3,050
337.7% 2022 6 30 2,150
2021
2021 6 30 500 2022 6 30
1.177
Leap Therapeutics
2022 6 30 2,690 2021 6 30
490 2022 6 30
2021 6 30
2022 6 30 (1) 21.0
(2) 237.0 35.0 (3)
37.5
23 2022
2021 12 31 483.1 64.3% 2022 6 30 172.3
3.0
2021 12 31 242.6 8.1% 2022 6 30 262.2
2022 2021
6 30 12 31
72,474 87,239
59,291 78,538
18,627 58,579
17,409 12,010
2,611 5,052
8,462 1,695
28,509 27,060
207,383 270,173
2021 12 31 587.6 7.7% 2022 6 30 633.1
2022 24
2022 6 30 2021 12 31 234.4 262.4
2022 2021
6 30 12 31
3 229,217 257,977
3 6 1,725 3,210
6 1 3,137 1,110
1 276 103
234,355 262,400
2022 6 30 2021 12 31
2022 2021
6 30 12 31
124,565 139,966
151,321 213,922
55,366 71,560
23,525 45,661
71,512 59,639
27,894 27,307
454,183 558,055
2021 12 31 558.1 18.6% 2022 6 30
454.2 2022 6 30
25 2022
2022 6 30 2021 12 31
2022 2021
6 30 12 31
4,535,409 4,382,887
1,172,554 2,241,962
565,936 629,678
(BMS)
2022 6 30
10 2021 6 30 4.138 2022 6
30 60
2017 9
2022 6 30
12
2021 1
6.5 2021 12
TIGIT
2022 1 3
2022 26
2022 2021 6 30
6 30
2022 2021
4,382,887 1,390,005
(616,522) (295,171)
869,103 543,544
(28,847) 143,050
(71,212) 5,257
152,522 396,680
4,535,409 1,786,685
2022 6 30 6.165 10
2.184 1.708
Leap
2021 6 30 2.952 4.138
1,760 1.363
27 2022
2022 6 30 8.691 11
1,150 9,540 7,500
2021 6 30 5.435 20
14 8,090 850 750
2022 6 30 2,880 1.154
6,760
1,900
2021 6 30 1.431 1.126
3,560
1,080 1,600
2022 6 30
530 7,120
2022 28
2020 5
29 2022
2022 6 30
71,364 14,282 57,082
109,700 51,358 58,342
565,936 380,729 185,207
40,909 13,896 27,013
698,687 254,109 444,578
12,750 4,250 8,500
25,173 5,743 19,430
7,484 1,536 5,948
308,141 308,141 –
1,840,144 1,034,044 806,100
2022 6 30 1.097
6,500 BMS 4,470 BMS
2022 30
3.807 1.852
12
12.5
2022 6 30
6.987
1,500 2022 6 30
1,280
2021 6 2022
6 30 2,520
2022 6 30
150
2022 6 30 3.081
31 2022
42 7,520 2022 4 29
2022 6 30
57
2022 6 30 2021 12 31
45 44 430 720
12 22
2022 6
30
100 2022 6 30 660 660
2022 32
2022 6 30 2021 12 31 1.723 4.831
2005
2022 6 30 2021 12 31 5.1%
2.3% 2022 6 30 1.177
33 2022
1994
(PBOC)
2022 6 30
2022 6 30
2021 12 31 10.1% 10.7% 2022 6
30
2022 6 30
2022 34
2022 6 30
2022 6 30
2022 6 30 8,600 2021 12 31 8,000
2022 6 30 662.2 2021 6 30 445.1
35 2022
2022 6 30 4.3 2021 12 31 7.2
2022 6 30
132.1 2021 12 31 145.8
2022 6 30 2021 12 31
2022 6 30 2021 6 30
1
2022 36
2022 6 30 XV
(a) XV 7 8
(b)
352 (c)
(1)
25,570,653(2) 1.90%
10,000,000(3) 0.74%
102,188 (4)
0.01%
7,727,927(5) 0.57%
29,439,115 (6)
2.19%
510,941 (7)
0.04%
545,597(8) 0.04%
1,584,167 (9)
0.12%
16,026,717 (10)
1.19%
172,372(11) 0.01%
4,253,998 (12)
0.32%
1,127,542(13) 0.08%
50 (14)
0.000004%
Margaret Han Dugan 73,918 (15)
0.01%
Donald W. Glazer 3,150,782(16) 0.23%
Michael Goller 413,335 (17)
0.03%
Anthony C. Hooper 143,988 (18)
0.01%
Ranjeev Krishana 413,335(19) 0.03%
Thomas Malley 1,326,083 (20)
0.10%
Alessandro Riva 73,918(21) 0.01%
Corazon (Corsee) D. Sanders 104,117 (22)
0.008%
404,053 (23)
0.03%
37 2022
(1) 2022 6 30 1,344,123,362
(2) (1) 1,627,205 (2) 23,499,740
(3) 443,708
(3) Roth IRA PENSCO
(4) The John Oyler Legacy Trust
(5)
(6) Oyler Investment LLC
Oyler Investment LLC 99%
(7) The Oyler Family Legacy Trust
(8) 545,597
(9)
(10) (1) 5,693,991 (2) 10,219,971
(3) 112,755
(11)
(12) Wang Investment LLC Wang Investment LLC 99%
(13)
(14)
(15) (1) Dugan Dugan 57,226
(2) Dugan 16,692
2022 38
(16) (1)Glazer 2,746,729 (2) Glazer Glazer
379,561 (3) Glazer 24,492
(17) (1)Goller 17,082 (2) Goller Goller 379,561
(3) Goller 16,692
(18) (1) Hooper Hooper 119,496
(2) Hooper 24,492
(19) (1) Krishana 17,082 (2) Krishana Krishana
379,561 (3) Krishana 16,692
(20) (1)Malley 407,082 (2) Malley Malley
902,309 (3) Malley 16,692
(21) (1) Riva Riva 57,226
(2) Riva 16,692
(22) (1) Sanders 7,800 (2) Sanders Sanders
79,625 (3) Sanders 16,692
(23) (1) 7,800 (2) 379,561
(3) 16,692
2022 6 30
(a) XV 7
8
(b) 352 (c)
39 2022
2022 6 30
XV 2 3
336
(1)
Amgen Inc. 246,269,426 18.32%
Julian C. Baker (2)
152,875,363 11.37%
Felix J. Baker(2) 152,875,363 11.37%
Baker Bros. Advisors (GP) LLC(2) 152,419,703 11.34%
Baker Bros. Advisors LP (2)
152,419,703 11.34%
Baker Brothers Life Sciences 139,823,423 10.40%
Capital, L.P.(2)
HHLR Fund, L.P.(3) 129,433,059 9.63%
HHLR Advisors, Ltd. (3)
133,587,655 9.94%
The Capital Group 106,958,925 7.96%
Companies, Inc. (4)
2022 40
(1) 2022 6 30 1,344,123,362
(2) Julian C. Baker Felix J. Baker Baker Bros. Advisors (GP) LLC Baker Bros. Advisors (GP) LLC
Baker Bros. Advisors LP BBA BBA 667, L.P. Baker Brothers Life Sciences, L.P.
Baker Brothers Life Sciences Capital, L.P. Baker Brothers Life Sciences, L.P.
BBA Michael Goller Ranjeev Krishana
BBA
Baker Brothers Life Sciences Capital, L.P. 2021 12 15 2021 12 15
140,543,649 Baker Brothers Life Sciences, L.P.
Julian C. Baker Felix J. Baker Baker Bros. Advisors (GP) LLC BBA 667, L.P.
11,152,058 Baker Brothers Life Sciences, L.P. 140,543,649 723,996
BBA Baker Brothers
Life Sciences Capital, L.P. Baker Brothers Life Sciences, L.P. 140,543,649 723,996
BBA
Julian C. Baker Felix J. Baker 270,868 FBB3 LLC
151,004
(3) (i)133,587,655 HHLR Fund, L.P. YHG Investment, L.P. (ii) 13,447,603 Hillhouse
BGN Holdings Limited HHLR Adrisors, Ltd. YHG Investment, L.P. HHLR Fund,
L.P. Hillhouse Capital Management, Ltd. Hillhouse Fund II, L.P.
Hillhouse Fund II, L.P. Hillhouse BGN Holdings Limited HHLR Adrisors, Ltd.
HHLR Fund, L.P. YHG Investment, L.P. 133,587,655 Hillhouse Capital
Management, Ltd. Hillhouse BGN Holdings Limited 13,447,603
Hillhouse Fund II, L.P. Hillhouse BGN Holdings Limited 13,447,603
(4) (i)13,112,463 Capital International, Inc. (ii) 628,966 Capital International Limited
(iii) 2,112,024 Capital International Sarl (iv) 89,056,893 Capital Research and
Management Company (v) 2,048,579 Capital Group Private Client Services, Inc.
Capital Group International, Inc. Capital Research and Management Company Capital
International, Inc. Capital International Limited Capital International Sarl Capital Group Private Client
Services, Inc. Capital Group International, Inc. Capital Bank and Trust Company The Capital
Group Companies, Inc. Capital Research and Management Company
Capital Group International, Inc. Capital International, Inc. Capital International Limited Capital
International Sarl Capital Group Private Client Services, Inc. 17,804,323
Capital Research and Management Company The Capital Group Companies Inc.
The Capital Group Companies Inc. Capital Research and Management Company
106,958,925
2022 6 30
XV 2 3
336
41 2022
1. 2011
2011 4 15 2015 4 17 2011 2016
2 2 2016 2011 2011
2022 6 30 2011 240 2011
2011 5 20 2016 1 31 2011
0.01 1.85
2011 2018 7 30
2022 1 1 2,908,297 2011 2022 6
30 2,702,945 2011 2022 1 1 2022 6 30
2011
2022 2022
1 1 6 30
2011 5 20 (1)
10 0.01 – – – – –
2013 4 3 (1)
10 0.01 879,267 – – – 879,267
2015 6 29 (1)
10 0.50 500,000 – – – 500,000
Thomas Malley 2016 1 25 (2)
10 1.85 552,752 – – – 552,752
2012 7 6 (3)
10 0.01 12 – – – 12
2013 4 3 (3)
10 0.01 12 – – – 12
2015 6 29 (3)
10 0.5 11 – – – 11
2011 5 20 976,243 – 205,348 4 770,891
2016 1 31 (3)
10 0.01
1.85
2,908,297 – 205,348 4 2,702,945
2022 42
(1) 20% 80% 20% 48
(2)
(3) 20%/25% 80%/75% 20%/25% 48/36
2. 2016
2018 11 7 2018 12 7 2016 2016
1 14 2016 2022 6 30 2016
74,437,232 5.
54% 2022 8 25 2016 76,217,465
2022 8 25 5.67%
2016 2020 4 13 2020 6 17
2016 2016
57,200,000 2016 2030 2022 4 17 2022 6
22 2016
2016 2016 2016 66,300,000
2016
2016
43 2022
2016 2022 6 22
10% 2016
30%
2016
12
1%
10
(i)
1/13 (ii)
1/13
2016
2016
2016 2030 4 13
2022 44
2016
2022 6 30 2016 1,066
2016 2016 2 8 2022 6 30
2016 0.5 28.81
2016 16
2022 1 1 54,065,073 2016 2022
6 30 63,489,698 2016
2022 2022
1 1 6 30
(1) (2)
2016 11 16 (3)
10 2.79 2.84 2,047,500 – – – 2,047,500
2017 9 27 (3)
10 6.73 7.70 935,000 – – – 935,000
2018 4 30 (3)
10 13.37 13.04 996,810 – – – 996,810
2018 6 26 (3)
10 12.70 12.34 1,310,088 – – – 1,310,088
2019 6 5 (3)
10 9.25 9.23 2,193,282 – – – 2,193,282
2020 6 17 (3)
10 13.33 13.42 1,821,976 – – – 1,821,976
2021 6 16 (3)
10 25.54 26.53 906,906 – – – 906,906
2022 6 22 (3)
10 11.74 11.98 – 1,887,678 – – 1,887,678
2016 11 16 (3)
10 2.79 2.84 1,613,430 – – – 1,613,430
2017 9 27 (3)
10 6.73 7.70 750,000 – – – 750,000
2018 6 26 (3)
10 12.70 12.34 655,044 – – – 655,044
2019 6 5 (3)
10 9.25 9.23 747,708 – – – 747,708
2020 6 17 (3)
10 13.33 13.42 560,599 – – – 560,599
2021 6 16 (3)
10 25.54 26.53 241,839 – – – 241,839
2022 6 22 (3)
10 11.74 11.98 – 471,913 – – 471,913
Anthony C. Hooper 2020 3 3 (5)
10 12.62 12.22 21,970 – – – 21,970
2020 6 17 (5)
10 13.33 13.42 45,383 – – – 45,383
2021 6 16 (5)
10 25.54 26.53 17,498 – – – 17,498
2022 6 22 (5)
10 11.74 11.98 – 34,645 – – 34,645
45 2022
2022 2022
1 1 6 30
(1) (2)
2016 2 8 (4) 10 2.61 2.42 188,926 – – – 188,926
2017 6 2 (5) 10 2.94 3.15 65,988 – – – 65,988
2018 6 6 (5) 10 15.73 16.15 17,442 – – – 17,442
2019 6 5 (5) 10 9.25 9.23 64,610 – – – 64,610
2020 6 17 (5) 10 13.33 13.42 45,383 – – – 45,383
2021 6 16 (5) 10 25.54 25.63 17,498 – – – 17,498
Margaret Han Dugan 2022 2 28 (5)
10 16.47 16.22 – 22,581 – – 22,581
2022 6 22 (5)
10 11.74 11.98 – 34,645 – – 34,645
Donald W. Glazer 2017 4 19 (4) 10 2.84 2.83 199,992 – – – 199,992
2018 6 6 (5) 10 15.73 16.15 17,442 – – – 17,442
2019 6 5 (5) 10 9.25 9.23 64,610 – – – 64,610
2020 6 17 (5) 10 13.33 13.42 45,383 – – – 45,383
2021 6 16 (5) 10 25.54 25.63 17,498 – – – 17,498
2022 6 22 (5) 10 11.74 11.98 – 34,645 – – 34,645
Michael Goller 2017 4 19 (4) 10 2.84 2.83 199,992 – – – 199,992
2018 6 6 (5) 10 15.73 16.15 17,442 – – – 17,442
2019 6 5 (5) 10 9.25 9.23 64,610 – – – 64,610
2020 6 17 (5) 10 13.33 13.42 45,383 – – – 45,383
2021 6 16 (5) 10 25.54 25.63 17,498 – – – 17,498
2022 6 22 (5) 10 11.74 11.98 – 34,645 – – 34,645
Ranjeev Krishana 2017 4 19 (4) 10 2.84 2.83 199,992 – – – 199,992
2018 6 6 (5) 10 15.73 16.15 17,442 – – – 17,442
2019 6 5 (5) 10 9.25 9.23 64,610 – – – 64,610
2020 6 17 (5) 10 13.33 13.42 45,383 – – – 45,383
2021 6 16 (5) 10 25.54 25.63 17,498 – – – 17,498
2022 6 22 (5) 10 11.74 11.98 – 34,645 – – 34,645
Thomas Malley 2017 6 2 (5) 10 2.94 3.15 169,988 – – – 169,988
2018 6 6 (5) 10 15.73 16.15 17,442 – – – 17,442
2019 6 5 (5) 10 9.25 9.23 64,610 – – – 64,610
2020 6 17 (5) 10 13.33 13.42 45,383 – – – 45,383
2021 6 16 (5) 10 25.54 25.63 17,498 – – – 17,498
2022 6 22 (5) 10 11.74 11.98 – 34,645 – – 34,645
Corazon D. Sanders 2020 8 24 (5)
10 18.50 18.26 27,482 – – – 27,482
2021 6 16 (5)
10 25.54 25.63 17,498 – – – 17,498
2022 6 22 (5)
10 11.74 11.98 – 34,645 – – 34,645
2022 46
2022 2022
1 1 6 30
(1) (2)
Alessandro Riva 2022 2 28 (5)
10 16.47 16.22 – 22,581 – – 22,581
2022 6 22 (5)
10 11.74 11.98 – 34,645 – – 34,645
2018 4 1 (4) 10 12.92 12.72 63,290 – – – 63,290
2019 6 5 (5) 10 9.25 9.23 64,610 – – – 64,610
2020 6 17 (5) 10 13.33 13.42 45,383 – – – 45,383
2021 6 16 (5) 10 25.54 25.63 17,498 – – 17,498 –
2017 4 19 (4) 10 2.84 2.83 199,992 – – – 199,992
2018 6 6 (5) 10 15.73 16.15 17,442 – – – 17,442
2019 6 5 (5) 10 9.25 9.23 64,610 – – – 64,610
2020 6 17 (5) 10 13.33 13.42 45,383 – – – 45,383
2021 6 16 (5) 10 25.54 25.63 17,498 – – – 17,498
2022 6 22 (5) 10 11.74 11.98 – 34,645 – – 34,645
2018 4 30 (6) 10 13.37 13.04 766,599 – – – 766,599
2019 6 5 (3) 10 9.25 9.23 797,550 – – – 797,550
2020 6 17 (3) 10 13.42 13.33 756,821 – – – 756,821
2021 6 16 (3) 10 25.54 25.63 483,678 – – – 483,678
2022 6 22 (3) 10 11.74 11.98 – 1,061,814 – – 1,061,814
2020 6 30 (3)
10 14.55 14.66 104,754 – – – 104,754
2021 6 16 (3)
10 25.54 26.53 177,853 – – – 177,853
2022 6 22 (3)
10 11.74 11.98 – 589,888 – – 589,888
2016 7 13 (3) 10 2.27 23.63 2.29 233,948 – 233,948 – –
2017 6 27 (3) 10 3.50 3.49 999,999 – 999,999 – –
2018 6 26 (3) 10 12.70 12.34 364,208 – – – 364,208
2019 6 5 (3) 10 9.25 9.23 558,285 – – – 558,285
2020 6 17 (3) 10 13.33 13.42 525,564 – – – 525,564
2021 6 16 (3) 10 25.54 26.53 332,527 – – – 332,527
2022 6 22 (3) 10 11.74 11.98 – 707,876 – – 707,876
2016 9 2 (3) 10 2.26 26.04 2.27 207,575 – – – 207,575
2017 6 27 (3) 10 3.50 3.49 850,465 – – – 850,465
2018 6 26 (3) 10 12.70 25.57 12.34 122,798 – – – 122,798
2019 6 5 (3) 10 9.25 27.34 9.23 211,276 – – – 211,276
2020 6 17 (3) 10 13.33 25.57 13.42 204,971 – – – 204,971
2021 6 16 (3) 10 25.54 26.53 157,196 – – – 157,196
47 2022
2022 2022
1 1 6 30
(1) (2)
2016 7 13 (3) 10 2.27 2.29 3,262,835 – – – 3,262,835
2016 7 22 (3) 10 2.13 12.47 2.10 105,487 – 6,500 – 98,987
2016 7 22 (6) 10 2.13 13.99 2.10 981,325 – 84,487 11 896,827
2016 7 29 (3) 10 2.11 2.02 26 – – – 26
2016 8 9 (3) 10 2.04 2.10 – – – – –
2016 8 22 (3) 10 2.28 2.24 – – – – –
2016 9 12 (3) 10 2.33 2.42 – – – – –
2016 9 19 (3) 10 2.51 2.38 – – – – –
2016 9 26 (3) 10 2.35 2.27 – – – – –
2016 10 12 (3) 10 2.48 2.42 134,498 – – – 134,498
2016 10 12 (6) 10 2.48 2.42 1,020 – – – 1,020
2016 10 17 (3) 10 2.42 2.55 61,399 – – – 61,399
2016 11 1 (3) 10 2.56 2.57 – – – – –
2016 11 7 (3) 10 2.43 2.46 – – – – –
2016 11 8 (3) 10 2.46 2.51 – – – – –
2016 11 16 (3) 10 2.79 2.84 – – – – –
2016 11 21 (3) 10 2.46 2.42 – – – – –
2016 11 28 (3) 10 2.49 17.48 2.38 39,000 – 39,000 – –
2016 11 30 (3) 10 2.43 2.44 1,274 – – – 1,274
2016 12 1 (3) 10 2.44 2.37 – – – – –
2016 12 9 (3) 10 2.07 2.09 34,099 – – – 34,099
2017 1 3 (3) 10 2.34 12.63 2.39 16,965 – 9,165 – 7,800
2017 1 5 (3) 10 2.44 2.39 63,661 – – – 63,661
2017 1 9 (3) 10 2.37 17.94 2.43 158,496 – 6,500 – 151,996
2017 1 17 (3) 10 2.51 2.53 – – – – –
2017 1 17 (6) 10 2.51 13.76 2.53 88,556 – 6,591 – 81,965
2017 1 23 (3) 10 2.46 13.53 2.49 108,875 – 57,330 – 51,545
2017 1 30 (3) 10 2.80 2.62 – – – – –
2017 2 1 (3) 10 2.68 2.77 144,989 – – – 144,989
2017 2 6 (3) 10 2.76 2.76 32,201 – – – 32,201
2017 2 8 (3) 10 2.67 2.78 – – – – –
2017 2 13 (3) 10 2.77 13.80 2.77 71,643 – 15,600 – 56,043
2017 2 27 (3) 10 2.97 2.93 – – – – –
2017 3 6 (3) 10 3.14 3.06 – – – – –
2017 3 13 (3) 10 3.08 3.02 142,701 – – – 142,701
2017 3 20 (3) 10 3.04 3.04 84,968 – – – 84,968
2017 3 27 (3) 10 2.79 2.79 – – – – –
2017 3 31 (6) 10 2.81 14.93 2.82 85,683 – 24,999 – 60,684
2017 4 3 (3) 10 2.82 2.82 5,928 – – – 5,928
2017 4 10 (3) 10 2.86 2.91 – – – – –
2017 4 11 (3) 10 2.91 2.95 – – – – –
2017 4 17 (3) 10 2.92 14.40 2.95 109,590 – 17,368 – 92,222
2017 4 24 (3) 10 2.82 2.89 – – – – –
2017 4 26 (3) 10 3.01 3.09 – – – – –
2017 5 1 (3) 10 3.14 3.13 531,245 – – – 531,245
2022 48
2022 2022
1 1 6 30
(1) (2)
2017 5 2 (6) 10 3.13 11.92 3.12 115,349 – 2,418 416 112,515
2017 5 3 (3) 10 3.12 3.12 11,999 – – – 11,999
2017 5 8 (3) 10 3.02 2.98 – – – – –
2017 5 10 (3) 10 2.88 2.92 – – – – –
2017 5 15 (3) 10 2.81 2.90 9,100 – – – 9,100
2017 5 30 (3) 10 2.88 2.88 21,060 – – – 21,060
2017 6 1 (6) 10 2.83 14.67 2.94 1,150,045 – 32,812 507 1,116,726
2017 6 12 (3) 10 2.99 10.69 3.00 12,844 – 117 – 12,727
2017 6 14 (3) 10 3.04 14.59 3.05 776,581 – 44,239 – 732,342
2017 6 15 (6) 10 3.05 13.77 3.04 4,029,896 – 339,235 10,088 3,680,573
2017 6 21 (3) 10 3.31 3.45 17,784 – – – 17,784
2017 6 23 (3) 10 3.41 3.45 – – – – –
2017 6 27 (3) 10 3.50 3.49 2,233,309 – – – 2,233,309
2017 6 29 (3) 10 3.50 3.45 43,654 – – – 43,654
2017 7 10 (3) 10 5.40 12.81 5.45 156,624 – 32,500 – 124,124
2017 7 17 (3) 10 5.67 13.24 4.19 41,106 – 29,120 – 11,986
2017 7 17 (6) 10 5.67 12.19 4.19 366,366 – 38,064 – 328,302
2017 7 24 (3) 10 5.95 5.65 – – – – –
2017 7 31 (3) 10 5.58 15.50 5.42 119,574 – 14,911 4,667 99,996
2017 7 31 (6) 10 5.58 13.67 5.42 371,072 – 5,005 – 366,067
2017 8 1 (3) 10 5.42 12.50 5.58 473,200 – 83,200 – 390,000
2017 8 2 (6) 10 5.58 5.45 – – – – –
2017 8 3 (3) 10 5.45 5.51 19,994 – – – 19,994
2017 8 7 (3) 10 5.56 5.95 114,309 – – – 114,309
2017 8 8 (3) 10 5.95 6.03 12,649 – – – 12,649
2017 8 10 (3) 10 5.95 5.59 – – – – –
2017 8 11 (3) 10 5.59 5.46 – – – – –
2017 8 17 (3) 10 5.39 5.32 18,317 – – – 18,317
2017 8 25 (3) 10 5.38 5.29 – – – – –
2017 8 28 (3) 10 5.29 5.28 24,167 – – – 24,167
2017 8 31 (3) 10 5.30 5.30 – – – – –
2017 8 31 (6) 10 5.30 11.14 5.30 281,242 – 50,518 3,471 227,253
2017 9 5 (3) 10 5.78 5.68 269,997 – – – 269,997
2017 9 12 (3) 10 5.39 5.43 – – – – –
2017 9 13 (3) 10 5.43 5.82 – – – – –
2017 9 18 (3) 10 6.22 6.37 22,269 – – – 22,269
2017 9 22 (3) 10 6.53 16.62 6.55 90,155 – 21,567 – 68,588
2017 9 25 (3) 10 6.55 11.72 6.56 153,569 – 31,577 – 121,992
2017 9 26 (3) 10 6.56 8.71 – – – – –
2017 9 29 (3) 10 7.49 7.96 37,492 – – – 37,492
2017 11 1 (3) 10 7.10 6.84 226,356 – – – 226,356
2017 11 30 (3) 10 6.38 6.15 10,764 – – – 10,764
2018 1 5 (3) 10 7.72 7.58 19,071 – – – 19,071
2018 1 31 (3) 10 9.52 12.79 10.44 84,385 – 3,393 – 80,992
2018 2 28 (3) 10 11.61 11.04 7,904 – – – 7,904
49 2022
2022 2022
1 1 6 30
(1) (2)
2018 4 30 (3) 10 13.37 13.04 17,407 – – 11,258 6,149
2018 6 26 (3) 10 12.70 14.86 12.34 935,961 – 18,252 3,042 914,667
2018 6 29 (3) 10 11.90 11.83 12,103 – – – 12,103
2018 8 31 (3) 10 13.67 13.66 13,741 – – – 13,741
2018 8 31 (7) 10 13.67 13.66 108,537 – – – 108,537
2018 9 28 (3) 10 13.28 13.25 65,433 – – – 65,433
2018 9 28 (8) 10 13.28 13.25 39,260 – – – 39,260
2018 11 30 (3) 10 11.07 11.79 11,028 – – – 11,028
2018 12 31 (3) 10 10.53 19.73 10.79 144,053 – 1,989 – 142,064
2018 12 31 (8) 10 10.53 10.79 12,727 – – – 12,727
2019 1 25 (3) 10 9.62 10.44 38,649 – – – 38,649
2019 2 28 (3) 10 10.77 10.54 130,754 – – – 130,754
2019 3 5 (3) 10 11.68 11.51 78,494 – – – 78,494
2019 5 10 (3) 10 9.33 10.32 44,213 – – – 44,213
2019 6 5 (3) 10 9.25 15.20 9.23 3,074,162 – 91,871 85,644 2,896,647
2019 6 28 (3) 10 9.67 9.53 38,714 – – 24,609 14,105
2019 8 30 (3) 10 11.14 11.06 97,201 – – – 97,201
2019 11 29 (3) 10 15.71 15.83 39,221 – – – 39,221
2019 12 31 (3) 10 12.80 12.92 29,523 – – – 29,523
2020 3 3 (3) 10 12.62 12.19 20,657 – – – 20,657
2020 3 31 (3) 10 9.65 9.67 294,775 – – – 294,775
2020 5 12 (3) 10 12.56 12.18 38,597 – – – 38,597
2020 5 29 (3) 10 12.49 12.73 21,281 – – – 21,281
2020 6 17 (3) 10 13.33 16.54 13.42 2,220,140 – 143 96,148 2,123,849
2020 6 30 (3) 10 14.55 14.66 212,771 – – – 212,771
2020 8 7 (3) 10 17.24 16.99 40,248 – – – 40,248
2020 8 31 (3) 10 18.69 18.85 14,040 – – 8,528 5,512
2020 9 30 (3) 10 21.65 22.03 8,021 – – – 8,021
2020 11 6 (3) 10 23.08 23.07 175,708 – – – 175,708
2020 11 30 (3) 10 21.99 20.99 26,962 – – 8,034 18,928
2021 1 22 (3) 10 27.46 28.81 64,441 – – 9,178 55,263
2021 2 26 (3) 10 25.36 25.81 6,331 – – – 6,331
2021 3 31 (3) 10 25.61 26.78 158,834 – – 10,010 148,824
2021 5 7 (3) 10 24.15 24.78 84,240 – – – 84,240
2021 5 28 (3) 10 27.00 27.58 121,485 – – – 121,485
2021 6 16 (3) 10 25.54 26.53 2,333,955 – – 70,161 2,263,794
2021 6 30 (3) 10 27.48 27.28 88,829 – – 29,432 59,397
2021 8 6 (3) 10 25.84 25.61 158,262 – – – 158,262
2021 8 31 (3) 10 23.22 23.72 153,322 – – – 153,322
2021 9 30 (3) 10 27.81 28.73 61,230 – – – 61,230
2021 11 5 (3) 10 28.38 28.08 45,786 – – – 45,786
2021 11 30 (3) 10 26.40 26.85 64,649 – – – 64,649
2021 12 31 (3) 10 21.03 20.84 59,332 – – – 59,332
2022 1 27 (3) 10 17.27 18.61 – 371,059 – – 371,059
2022 2 28 (3) 10 16.47 16.22 – 171,626 – – 171,626
2022 50
2022 2022
1 1 6 30
(1) (2)
2022 3 31 (3) 10 15.85 15.46 – 135,694 – – 135,694
2022 5 6 (3) 10 12.27 12.50 – 80,821 – – 80,821
2022 5 31 (3) 10 10.30 10.56 – 123,604 – – 123,604
2022 6 22 (3) 10 11.74 11.98 – 6,122,831 – – 6,122,831
2022 6 30 (3) 10 12.48 12.81 – 77,974 – – 77,974
54,065,073 12,159,745 2,342,418 392,702 63,489,698
(1) 13
(2) 13
(3) 25%
75% 25% 36
(4)
(5)
(6) 20% 80% 20% 48
(7) 48
(8)
51 2022
2016
2022 6 22 2022 4 19
2022 6 22 2022
25,693
6,423 Anthony
C.Hooper Margaret Han Dugan Donald W. Glazer Michael Goller Ranjeev
Krishana Thomas Malley Alessandro Riva Corazon (Corsee) D. Sanders
1,284 567,736
3. 2018
2018 11 7 2018 12 7 2018
2018 6 6 2018 2019 6 5 2018
2021 6 2018
2021 9 1 2018
2022 6 30 2,827,929 2018
2018 15%
2018 2018
2018 2018 5%
2022 52
2018
1% 10% 25,000
3 1 9 1
85%
2018
4. 2018
2018 6 6 2018 12,000,000
2018
2018 8 7 2018
2022 6 30 2018 2018
2018 8 31 2018 13.66
2021 12 31 2018 9,334,659
0.7%
2022 6 30 2018 2022 6 22
2018 9,372,895 2022 6 30
0.7%
53 2022
2022 6 22 2016 2018
2018 16
2022 1 1 30,901 2018 2022 6 30
30,901 2018
2022 2022
1 1 6 30
(1) (2)
2018 8 31 (3)
10 13.67 25.49 13.66 30,901 – – – 30,901
30,901 – – – 30,901
(1) 13
(2) 13
(3) 25%
75% 25% 36
2018
5635(c)(4)
2018
2022 54
2018 12,000,000
2018
2018
2022 6 22 2016 2018
2018
12
1%
10
(i)
1/13 (ii)
1/13
2018
55 2022
C.2.1
Ranjeev Krishana
2022 56
3.21 D.3.3 D.3.7
Thomas Malley Corazon
(Corsee) D. Sanders Anthony C. Hooper Thomas Malley
3.10(2) 3.21
3.25 E.1.2
Margaret Han Dugan Ranjeev Krishana Margaret
Han Dugan 2022 6 22
Margaret Han Dugan 2022 9 13
B.3.1
Donald W. Glazer Michael Goller Alessandro Riva
Anthony C. Hooper Donald W. Glazer
57 2022
B.8
2022 1 1
2022 58
13.51(B)(1)
13.51(B)(1)
2022 1 31
Margaret Han Dugan 2022 2 1
2022 2 25
Alessandro Riva 2022 2 1
2022 6 22
Margaret Han Dugan 2022 9 13
2020 1 2
174.85 15,895,001 206,635,013
20.5% 2,779,241,000 (a) 2019
10 30 30 36% (b)
1.00 7.84 2019 10 31
26% (c) 2019 10 31 26%
59 2022
2019 11 29
2022 6 30
2022
2021 2022 6 30
12 31 6 30
(%)
(a)
2,779,241 100% 1,869,643 1,984,939 794,302
(a) 12.5
2019 11 29
2025
2019 11 1 2019 12 9 2020 1 3
2020 9 24
20.6%
20.4%
75,000,000
90
2020 12 1 (a)
20% (b) 60 (c)
2022 60
2020 3 18 2020 9 25 2020 10
9
2021 9 165,529
2,151,877 50,000,000 2022 6 30
50,000,000
2020 7
2020 7 15 2020
202,995,338 2020 7 12
14.2308 185 145,838,979
20.8
(a)
(b)
(c)
(d)
2020 7 13 2020 7 16
2022 6 30 19.2 1.5
61 2022
2021 12 15 )
2021 6 16 2021
192.60 234.89 391.68
115,055,260
3,392,616,000 (
) (i) (ii) (iii) (iv)
(v)
2020 11 16 2021 1 29 2021 4 20 2021 5 14
2021 6 1 2021 6 21 2021 6 28 2021 6 30 2021 7 9 2021 7 28
2021 10 15 2021 11 16 2021 11 23 2021 11 24 2021 11 29
2021 11 30 2021 12 2 2021 12 6 2021 12 7 2021 12 13 2021 12
21 2021 12 28 2022 4 29 2021 4 30
2022 62
2022 6 30 47 169
2022 6 30
2022
2021 2022 6 30
12 31 6 30
13,245,940 – 3,309,549 9,936,391
467,700 – 348,120 119,580
150,000 – 91,092 58,908
136,360 – 62,207 74,153
6,000,000 – 913,798 5,086,202
1,630,155 – – 1,630,155
21,630,155 – 4,724,766 16,905,389
2022 6 30
23
63 2022
2022 2021 6 30
2022 2021 6 30
3000
3000
(i) 23 23
2022 2021 6 30
2022 6 30 2021 12 31
(ii) 23
(iii) 23
2022 64
3000
(i) 23
(ii) 23
(iii) 23
Thomas Malley Anthony C. Hooper Corazon (Corsee) D.
Sanders Thomas Malley Corazon (Corsee) D. Sanders Anthony C.
Hooper Thomas Malley
2022 6 30
65 2022
2022 6 30
13.20 13.21 13.22
2022 8 26
2022 66
6 30
2022 2021
13 566,084 244,741
3 82,114 511,123
648,198 755,864
136,410 68,948
768,122 676,817
625,976 414,395
376 375
1,530,884 1,160,535
(882,686) (404,671)
21,502 (9,045)
(117,650) (4,990)
(978,834) (418,706)
9 26,889 (4,860)
(1,005,723) (413,846)
(0.75) (0.35)
15 1,334,252,648 1,191,521,766
(9.80) (4.52)
102,634,819 91,655,520
67 2022
6 30
2022 2021
(1,005,723) (413,846)
(88,085) 5,864
– 361
(12,315) (1,072)
(1,106,123) (408,693)
2022 68
2022 2021
6 30 12 31
4,531,137 4,375,678
4 333 328
4 1,172,554 2,241,962
5 172,259 483,113
6 262,210 242,626
10 207,383 270,173
6,345,876 7,613,880
4 3,939 6,881
7 633,100 587,605
117,583 117,431
8 43,325 46,679
9 103,429 110,424
10 130,955 163,049
1,032,331 1,032,069
7,378,207 8,645,949
11 234,355 262,400
10 454,183 558,055
3 163,396 187,414
9 15,564 21,395
24,788 21,925
3 125,394 120,801
12 380,729 427,565
1,398,409 1,599,555
69 2022
2022 2021
6 30 12 31
12 185,207 202,113
3 167,570 220,289
41,921 43,041
9 14,739 14,169
3 219,385 269,561
10 48,432 54,234
677,254 803,407
2,075,663 2,402,962
20
0.0001
9,500,000,000
2022 6 30 2021 12 31
1,349,639,439
1,334,804,281 134 133
11,356,686 11,191,007
17 (82,450) 17,950
(5,971,826) (4,966,103)
5,302,544 6,242,987
7,378,207 8,645,949
2022 70
2021 12 31 1,334,804,281 133 11,191,007 17,950 (4,966,103) 6,242,987
– – (152) – – (152)
2,165,904 – – – – –
12,669,254 1 18,971 – – 18,972
– – 146,860 – – 146,860
– – – (100,400) – (100,400)
– – – – (1,005,723) (1,005,723)
2022 6 30 1,349,639,439 134 11,356,686 (82,450) (5,971,826) 5,302,544
2020 12 31 1,190,821,941 118 7,414,932 6,942 (3,552,749) 3,869,243
(1,722,773) – – – – –
15,467,855 2 35,599 – – 35,601
– – 110,624 – – 110,624
– – – 5,153 – 5,153
– – – – (413,846) (413,846)
2021 6 30 1,204,567,023 120 7,561,155 12,095 (3,966,595) 3,606,775
71 2022
6 30
2022 2021
(1,005,723) (413,846)
32,061 21,159
16 146,860 110,624
4 23,529 6,033
– 53,500
3 (45,583) (53,902)
7,550 (12,311)
6,360 11,212
307,430 (13,338)
(31,633) (28,294)
32,315 (77,204)
(30,362) (42,558)
19,525 1,688
(76,737) 138,877
(2,114) 3,189
(616,522) (295,171)
(95,421) (80,920)
(11,504) (1,357,051)
1,051,028 1,997,515
(75,000) (8,500)
– (7,500)
869,103 543,544
2022 72
6 30
2022 2021
12 – 10,819
12 67,586 112,589
12 (115,405) (15,959)
18,972 35,601
(28,847) 143,050
(71,212) 5,257
152,522 396,680
4,382,887 1,390,005
4,535,409 1,786,685
4,531,137 1,776,448
333 310
3,939 9,927
24,436 14,527
12,899 14,267
58,676 28,885
– 45,000
73 2022
1.
BTK)
PD-1
PARP1 PARP2
13
2,500 40 80
30
3 16,000
CMO
2010 29
8,600
2022 74
1.
2022 6 30 45
BeiGene 101 – 100%
BeiGene AUS Pty Ltd 56,947,230 100%
BeiGene Australia
* 100%
902,345,067
* 100%
10,450,000,000
BeiGene (Canada) ULC 100 100%
BeiGene ESP, S.L. 3,000 100%
BeiGene France Sarl 7,500 100%
* 100%
8,870,000,000
* 263,000,000 100%
BeiGene Germany GmbH 25,000 100%
BeiGene (Hong Kong) Co., Limited 1 100%
7,700,000,000
* 4,000,000 100%
75 2022
1.
BeiGene International GmbH 20,000 100%
BeiGene (Italy) S.R.L 10,000 100%
BeiGene Brazil Ltda. 2,450,190 100%
BeiGene Poland sp. z o.o. 5,000 100%
BeiGene Sweden AB 25,000 100%
BeiGene Turkey Medical Products 10,000 100%
Trade Limited Company
BeiGene Ireland Limited – 100%
BeiGene Ireland
BeiGene Japan, Ltd. 1,781,660 100%
BeiGene Korea Y.H. 100,000,000 100%
BeiGene Netherlands B.V – 100%
BeiGene NZ Unlimited 100,000 100%
BeiGene NZ, Limited
BeiGene Pharmaceuticals GmbH 20,000 100%
2022 76
1.
* 100%
3,800,000
BeiGene Pharmaceuticals Israel Limited – 100%
* 100%
7,000,000
* 1,000,000 100%
* 100%
934,344,311
* – 100%
* 100%
270,000,000
BeiGene Singapore Pte. Ltd. 1 100%
* 100%
2,673,218,389
BeiGene Switzerland GmbH 20,000 100%
BeiGene Switzerland
77 2022
1.
168,000,000 100%
BeiGene UK, Ltd. BeiGene UK 142 100%
BeiGene United Kingdom, Ltd. 110 100%
BeiGene USA, Inc. BeiGene USA 1 100%
BeiGene US Holdings, LLC – 100%
BeiGene US Manufacturing Co., Inc. 156,000,000 100%
BeiGene Hopewell Urban Renewal, LLC 115,000,000 100%
Pi Health, Ltd. 12,000,000 100%
Pi Health USA, LLC 5,000,000 100%
B10 Health Technologies Private Limited – 100%
Newco 101 – 100%
*
2022 78
1.
2022 6 30 2022 2021 6 30
2022 2021 6 30 2022
2021 6 30
10-Q
S-X 10
2021 12 31 10-K
2022 6 30
79 2022
1.
2021 11 2021-10 832
2021 12 15
2021 12 31
2022 6 30
2022 80
2.
1
2 1
3
2022 6 30 2021 12 31
2022 6 30 1 2 3
384,121 – –
257,614 – –
4
1,172,554 – –
4 :
8,451 3,003 –
– – 5,000
1,822,740 3,003 5,000
81 2022
2.
2021 12 31 1 2 3
107,855 – –
315,564 – –
4
2,241,962 – –
4 :
23,809 10,306 –
2,689,190 10,306 –
3
Leap Therapeutics, Inc. Leap
2020 1 2021 9 Leap
Leap 1
Leap 2
4
3
2022 6 30 2021 12 31
2022 82
3.
2022 2021 6 30
2022 2021 6 30
6 30
2022 2021
– 484,646
24,240 26,477
52,497 –
5,377 –
82,114 511,123
2021 1
83 2022
3.
650,000,000
1,300,000,000
250,000,000
606
(1)
(2)
(3)
606
2022 84
3.
650,000,000
1,231,000,000
420,000,000 484,646,000
165,354,000
2021 6 30
2021 6 30
2022 6 30 20,656,000
2021 6 30 26,477,000
2022 6 30 5,377,000
85 2022
3.
2021 12
TIGIT
5
2022
2022 1 300,000,000
2023 2023 2023
600,000,000 700,000,000
745,000,000 1,150,000,000
50%
25%
606
(1)
(2) (3)
(4)
2022 86
3.
300,000,000
71,980,000
213,450,000
14,570,000
87 2022
3.
2022 6 30
52,497,000 2022 6
30 3,584,000
2019 10
2020 1 2
XGEVA 2019
2020 11 2020 7
2020 12
B 2021 7
2022 4
CD19
B
2022 88
3.
1,250,000,000
KRAS G12C LUMAKRAS(sotorasib)
LUMAKRAS
808 100%
2022 4 20
89 2022
3.
2019 10
2020 1 2 174.85 15,895,001
20.5%
Anthony Hooper 2020 1
132.74
2,109,902,000
601,857,000 2,779,241,000
2,162,407,000 616,834,000
2022 2021 6 30
6 30
2022 2021
46,789 55,330
45,583 53,903
92,372 109,233
2022
6 30
698,687
2022 90
3.
2022 6 30 2021 12 31
2022 2021
6 30 12 31
125,394 120,801
219,385 269,561
344,779 390,362
2022 2021 6 30
6 30
2022 2021
3,478 678
898 63
(26,642) (15,917)
(22,266) (15,176)
2022 6 30
30,061,000 2021 6 30 18,854,000 2022 6
30 2021 12 31 101,580,000 106,790,000
91 2022
4.
2022 6 30 2021 12 31 4,272,000 7,209,000
2022 6 30
1,184,869 – 12,315 1,172,554
1,184,869 – 12,315 1,172,554
2021 12 31
2,245,662 – 3,700 2,241,962
2,245,662 – 3,700 2,241,962
2022 6 30
2022 6 30
2022 92
4.
Leap Therapeutics, Inc. (Leap)
2020 1 Leap 5,000,000 Leap B
B 2020 3 Leap Leap
2021 9 Leap 7,250,000
Leap 2022 6 30 Leap
8.3% Leap
13.1%
2022 6 30 22,661,000 2021
6 30 5,376,000 2022 6 30 2021 12 31
2022 2021
6 30 12 31
Leap 8,451 23,809
Leap 3,003 10,306
2022 6 30 2021 12 31 44,033,000
43,722,000 2022 6 30
366,000
93 2022
4.
2022 6 30 2021 12 31 27,100,000 22,955,000
2022 6 30 1,234,000 2021 6 30
657,000
5.
2022 2021
6 30 12 31
172,467 483,528
(208) (415)
172,259 483,113
45 90
2022 2021
6 30 12 31
3 171,294 483,058
3 6 965 55
172,259 483,113
2022 94
5.
2022 2021 6 30
6 30
2022 2021
415 112
(210) (46)
– –
3 1
208 67
6.
2022 2021
6 30 12 31
82,848 78,140
37,992 9,397
141,370 155,089
262,210 242,626
95 2022
7.
2022 2021
6 30 12 31
65,485 65,485
131,885 118,203
50,878 50,288
179,495 144,083
138,478 119,585
36,473 27,404
602,694 525,048
(142,561) (124,286)
172,967 186,843
633,100 587,605
2021 11 75,197,000 42
2022 6 30 30,041,000 2021 6 30
20,667,000
2022 96
8.
2022 6 30 2021 12 31
2022 6 30 2021 12 31
7,500 (3,625) 3,875 7,500 (3,250) 4,250
42,016 (2,566) 39,450 43,394 (965) 42,429
816 (816) – 816 (816) –
50,332 (7,007) 43,325 51,710 (5,031) 46,679
BMS
10
2018 9 2020 2
2024 2
97 2022
8.
12
6 30
2022 2021
1,644 117
376 375
2,020 492
2022 6 30
12 31
2022 1,614 375 1,989
2023 3,222 750 3,972
2024 3,222 750 3,972
2025 3,222 750 3,972
2026 3,222 750 3,972
2027 24,948 500 25,448
39,450 3,875 43,325
2022 98
9.
2022 6 30 26,889,000 2021 6 30
4,860,000 2022 6 30
2021 6 30
2022
6 30
2022 6 30 11,765,000 12
2022 6 30
1,840,000
2022 6 30 2021 12
31
2022
6 30 2013 2022 2012 2022
2018 2022 2015 2022
2011 2022
99 2022
10.
2022 2021
6 30 12 31
72,474 87,239
59,291 78,538
18,627 58,579
17,409 12,010
2,611 5,052
8,462 1,695
28,509 27,060
207,383 270,173
2022 2021
6 30 12 31
109 109
14,412 14,140
(1)
21,473 24,237
29 17,162
7,345 6,609
4 87,587 100,792
130,955 163,049
(1)
2022 100
10.
2022 2021
6 30 12 31
124,565 139,966
151,321 213,922
55,366 71,560
23,525 45,661
71,512 59,639
27,894 27,307
454,183 558,055
2022 2021
6 30 12 31
40,835 46,352
7,484 7,814
113 68
48,432 54,234
101 2022
11.
2022 2021
6 30 12 31
3 229,217 257,977
3 6 1,725 3,210
6 1 3,137 1,110
1 276 103
234,355 262,400
12.
2022 6 30 2021 12 31
2022 6 30 2021 12 31
2018 4 4 580,000 9 2027 4 4 (1) 4,330 29,000 1,255 8,000
2020 1 22 (2) 9 2029 1 20 (2) 1,493 10,000 1,569 10,000
2020 11 9 378,000 9 2029 11 8 (3) 2,613 17,500 – –
2020 9 24 200,000 (4) 4.5% 200,000 1,339,585 200,000 1,274,535
2020 9 24 500,000 (5) 4.5% 14,930 100,000 15,693 100,000
2022 2 25 50,000 1 2023 2 25 2.2% 50,000 334,896 – –
(6) 107,363 719,115 209,048 1,332,197
380,729 2,550,096 427,565 2,724,732
2018 4 4 580,000 9 2027 4 4 (1) 81,368 545,000 89,444 570,000
2020 1 22 (2) 9 2029 1 20 (2) 50,016 335,000 53,353 340,000
2020 11 9 378,000 9 2029 11 8 (3) 53,823 360,500 59,316 378,000
185,207 1,240,500 202,113 1,288,000
2022 102
12.
1. 2022 6 30
4.9%
2022 6 30 598,000 4,000,000
2. 2020 1 22
1,100,000,000
2020 12 31
1,100,000,000 350,000,000 2022 6 30
4.4% 2022 6 30 771,000
5,000,000 2017 3 3
3. 2022 6 30
4.3%
4. 2020 9 200,000,000
120,000,000
80,000,000
2021 10 8
2021 10 8 2022 10 8
2017 1 25
5. 2020 9
73,640,000
500,000,000 14,728,000 100,000,000
58,912,000 400,000,000
(i)2021 11 9
(ii) 2021 10 8
(i)2022 11 9
(ii) Hillhouse Capital
Hillhouse Capital Hillhouse Capital
6. 2021 12 31 2020 12 31
1,760,000,000 2021 4 19 2023
5 24 2022 6 30 17,586,000 117,000,000
114,036,000 730,082,000 2022 6 30
4.1%
103 2022
12.
2022 6 30 10,984,000 1,935,000
2021 6 30 14,577,000 251,000
13.
2022 2021 6 30
6 30
2022 2021
638,273 291,794
(72,189) (47,053)
566,084 244,741
2022 2021 6 30
6 30
2022 2021
233,072 64,513
192,522 123,758
41,576 26,775
29,008 17,792
19,798 –
21,396 –
8,405 –
8,946 6,961
4,577 2,221
6,784 2,721
566,084 244,741
2022 104
13.
2022 2021 6 30
6 30
2022 2021
59,639 11,874
72,189 47,053
(60,316) (33,355)
71,512 25,572
14.
6 30
2022 2021
136,410 68,948
30,041 20,784
768,122 676,817
13,366 10,141
2,020 375
489,416 316,935
146,860 110,632
25,966 17,523
662,242 445,090
118,355 2,460
(32,520) (5,534)
73 –
2022 2021 6 30 293,291,000 220,110,000
105 2022
15.
6 30
2022 2021
(1,005,723) (413,846)
1,334,252,648 1,191,521,766
2022 2021 6 30
16.
2016
2016 1 NASDAQ (IPO)
2016 2016 2016 2 65,029,595
2016 2011 2011
2016 2011
2022 6 30 2011
2016 5,166,510 2018 12 2016
38,553,159 2020 6
2016 57,200,000
2030 4 13 2016
2022 6 30 2016 12,159,745 33,193,771
2022 6 30 2016
63,489,649 57,144,906 2022 6 30 2016 74,479,333
2022 106
16.
2016
2016 2016
2016 66,300,000 2022 3 31
5% 2022 6 22
2018
2018 6 2018 2018 12,000,000
5635(c)(4) 5635(c)(4)
2018 2018
2016 2018 8
2018
2022 6 30 2018 2022 6
30 2018 30,901 408,408
2016 2018 2022 6 22
107 2022
16.
2018
2018 6 2018 3,500,000
2018 12
3,855,315 7,355,315 2019 6
2021 6
2021 9 1
6
15%
10%
2022 6 30 4,527,386
1 2
2022 2 28 667,160 210.52 16.19 178.94 13.76 9,183
2021 8 31 425,386 308.30 23.72 262.06 20.16 8,575
2021 2 26 436,124 236.30 18.18 200.86 15.45 6,738
1.
2.
2022 108
16.
2022 2021 6 30
6 30
2022 2021
67,965 52,082
78,895 58,542
146,860 110,624
17.
2021 12 31 27,898 (3,700) (6,248) 17,950
(88,085) (12,315) – (100,400)
– – – –
(88,085) (12,315) – (100,400)
2022 6 30 (60,187) (16,015) (6,248) (82,450)
109 2022
18.
2019 10 31 2019 12 6 2020 9 24
2021 9 165,529
2,151,877 50,000,000
2021 12
192.60
391.68 115,055,260
3,392,616,000
19.
10%
50%
2022 110
19.
10%
2022 6 30 2021 12 31 2,448,530,000
799,574,000
20.
2022 6 30 109,700,000 65,020,000
44,680,000
2022 6 30 308,141,000
1,250,000,000 2022 6 30
698,687,000
111 2022
20.
2021 6
2022 6 30 25,173,000
15,000,000 2022 6 30
12,750,000
2022 6 30
1,536,000
CRO
2022 112
21.
(a) 2022 2021 6 30
2022 2021
6 30 (i) 50,000 2021
50,000 (ii) 75,000 2021 75,000 (iii)
2,141,000 2021 2,271,000
(b)
6 30
2022 2021
3,423 2,945
37 65
19,626 17,635
23,086 20,645
113 2022
22.
6 30
2022 2021
403,164 218,617
213,749 383,809
31,285 153,438
648,198 755,864
2022 2021 6 30 2022 6 30
57,480,000
156,269,000
2021 6 30 357,786,000
26,023,000 2022 6 30 24,634,000
6,651,000 2021 6 30
2022 114
23.
2022 6 30
(i) (iii)
(768,122) (5,520) – (773,642)
(625,976) (4,044) – (630,020)
(978,834) (9,564) – (988,398)
(26,889) 1,082 (11,385) (37,192)
(1,005,723) (8,482) (11,385) (1,025,590)
(1,005,723) (8,482) (11,385) (1,025,590)
115 2022
23.
2021 6 30
(i) (iii)
(676,817) 34,210 – (642,607)
(414,395) 18,197 – (396,198)
(418,706) 52,407 – (366,299)
4,860 (4,125) (21,801) (21,066)
(413,846) 48,282 (21,801) (387,365)
(413,846) 48,282 (21,801) (387,365)
2022 116
23.
2022 6 30
(i) (ii) (iii)
103,429 1,082 – (9,662) 110,169
15,320* – –
7,378,207 16,402 – (9,662) 7,384,947
11,356,686 9,564 307,894* 1,723 11,985,971
174,049* – 136,055*
(5,971,826) (9,564) (307,894)* (11,385) (6,594,371)
1,082 – –
(158,729)* – (136,055)*
5,302,544 16,402 – (9,662) 5,309,284
117 2022
23.
2021 12 31
(i) (ii) (iii)
110,424 5,253 – – 125,744
10,067* – –
8,645,949 15,320 – – 8,661,269
11,191,007 48,730 – 56,237 11,809,005
125,319* 307,894* 79,818*
(4,966,103) (48,730) – (56,237) (5,568,781)
5,253 – –
(115,252)* (307,894)* (79,818)*
6,242,987 15,320 – – 6,258,307
*
(i)
2022 6 30
9,564,000 2021 6 30 52,407,000
2022 6 30 1,082,000 2021 6 30
4,125,000
2022 118
23.
(i)
2021 12 31
174,049,000 15,320,000
158,729,000 2021 12 31 2022 1 1
(ii)
2016 2 307,894,000
307,894,000
119 2022
23.
(iii)
2016-
09
2022 6 30 9,662,000
2021 6 30
2022 6 30 1,723,000 2021 6 30
21,801,000
2021 12 31 136,055,000 136,055,000
2022 1 1
(iv)
16
2022 6 30
2022 6 30
2022 120
23.
(v)
2022 6 30
2022 6 30
24.
2022 6 30 2021 6 30
121 2022
2011 2011 4 15 2015 4 17 2011
2016 2016 1 14 2016
2022 4 29
2018 2018 11 7 2018 12 7
2018 2018 6 6
2018 2021 6
16 2021 9 1
2018 2018 6 6 2018 8 7
2018 2018
ADS 13
1987 4 7
2019 10 31
2020 1 2
2019 10 31
2018 12 7
2022 122
2010 10 28
2017 1 25
2017 3 3
BeiGene Switzerland GmbH 2017 9 1
622
123 2022
FDA (U.S. Food and Drug Administration)
1998 11 27
2022 124
NMPA (National Medical Products Administration)
Novartis Pharm AG
2018 7 30
2022 6 30
571
125 2022
15
2022 126
BLA
BRAF B-raf
BTK B
CLL
ESCC
MCL
PARP ADP
DNA DNA
PD-1 1 T pro-B
PD-L1 PD-L2 PD-1
T
127 2022
RAF RAF BRAF-BRAF
BRAF-CRAF CRAF-CRAF
sBLA
SLL
T T T
B
TIM-3 T 3 Th1
WM
2022 128